These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 25426808)

  • 1. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
    Cohan D; Natureeba P; Koss CA; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Gandhi M; Clark TD; Nzarubara B; Achan J; Ruel T; Kamya MR; Havlir DV
    AIDS; 2015 Jan; 29(2):183-91. PubMed ID: 25426808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women.
    Natureeba P; Ades V; Luwedde F; Mwesigwa J; Plenty A; Okong P; Charlebois ED; Clark TD; Nzarubara B; Havlir DV; Achan J; Kamya MR; Cohan D; Dorsey G
    J Infect Dis; 2014 Dec; 210(12):1938-45. PubMed ID: 24958908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.
    Koss CA; Natureeba P; Mwesigwa J; Cohan D; Nzarubara B; Bacchetti P; Horng H; Clark TD; Plenty A; Ruel TD; Achan J; Charlebois ED; Kamya MR; Havlir DV; Gandhi M
    AIDS; 2015 Apr; 29(7):825-30. PubMed ID: 25985404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.
    Koss CA; Natureeba P; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Clark TD; Achan J; Ruel T; Nzarubara B; Kamya MR; Havlir DV; Cohan D
    J Acquir Immune Defic Syndr; 2014 Oct; 67(2):128-35. PubMed ID: 25072616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
    Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estradiol Levels Are Altered in Human Immunodeficiency Virus-Infected Pregnant Women Randomized to Efavirenz-Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy.
    McDonald CR; Conroy AL; Gamble JL; Papp E; Hawkes M; Olwoch P; Natureeba P; Kamya M; Silverman M; Cohan D; Koss CA; Dorsey G; Kain KC; Serghides L
    Clin Infect Dis; 2018 Jan; 66(3):428-436. PubMed ID: 29136115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding.
    Gandhi M; Mwesigwa J; Aweeka F; Plenty A; Charlebois E; Ruel TD; Huang Y; Clark T; Ades V; Natureeba P; Luwedde FA; Achan J; Kamya MR; Havlir DV; Cohan D;
    J Acquir Immune Defic Syndr; 2013 Aug; 63(5):578-84. PubMed ID: 24135775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
    Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
    J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
    Coovadia A; Abrams EJ; Strehlau R; Shiau S; Pinillos F; Martens L; Patel F; Hunt G; Tsai WY; Kuhn L
    JAMA; 2015 Nov; 314(17):1808-17. PubMed ID: 26529159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.
    Ruel TD; Kakuru A; Ikilezi G; Mwangwa F; Dorsey G; Rosenthal PJ; Charlebois E; Havlir D; Kamya M; Achan J
    J Acquir Immune Defic Syndr; 2014 Apr; 65(5):535-41. PubMed ID: 24326597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
    João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
    Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
    Murnane PM; Strehlau R; Shiau S; Patel F; Mbete N; Hunt G; Abrams EJ; Coovadia A; Kuhn L
    Clin Infect Dis; 2017 Aug; 65(3):477-485. PubMed ID: 28419200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class-sparing regimens for initial treatment of HIV-1 infection.
    Riddler SA; Haubrich R; DiRienzo AG; Peeples L; Powderly WG; Klingman KL; Garren KW; George T; Rooney JF; Brizz B; Lalloo UG; Murphy RL; Swindells S; Havlir D; Mellors JW;
    N Engl J Med; 2008 May; 358(20):2095-106. PubMed ID: 18480202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV.
    Conroy AL; McDonald CR; Gamble JL; Olwoch P; Natureeba P; Cohan D; Kamya MR; Havlir DV; Dorsey G; Kain KC
    Am J Obstet Gynecol; 2017 Dec; 217(6):684.e1-684.e17. PubMed ID: 29031892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
    Okomo U; Togun T; Oko F; Peterson K; Townend J; Peterson I; Jaye A
    BMC Pediatr; 2012 Jul; 12():95. PubMed ID: 22770231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
    Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review.
    Pasley MV; Martinez M; Hermes A; d'Amico R; Nilius A
    AIDS Rev; 2013; 15(1):38-48. PubMed ID: 23449228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
    Domingo P; Suárez-Lozano I; Torres F; Teira R; Lopez-Aldeguer J; Vidal F; Muñoz A; Viciana P; Lozano F; Vergara A; Roca B; García Alcalde ML; Cosín J; Terrón A; Galindo MJ; Geijo P; Ribera E; Gonzalez J; Sanchez T; Lacalle JR; Garrido M
    J Antimicrob Chemother; 2008 Jun; 61(6):1348-58. PubMed ID: 18356150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
    Röshammar D; Simonsson US; Ekvall H; Flamholc L; Ormaasen V; Vesterbacka J; Wallmark E; Ashton M; Gisslén M
    J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):727-42. PubMed ID: 21964996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.